Corline Biomedical AB (CLBIO.ST)

SEK 8.76

(5.29%)

Market Cap (In SEK)

214.53 Million

Revenue (In SEK)

25.03 Million

Net Income (In SEK)

-1.8 Million

Avg. Volume

6167.00

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
5.98-16.8
PE
-
EPS
-
Beta Value
0.421
ISIN
SE0006887451
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Henrik Nittmar Ph.D.
Employee Count
-
Website
https://www.corline.se
Ipo Date
2015-06-03
Details
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.